BioCentury
ARTICLE | Clinical News

Latest data show survival benefit for Ganymed's IMAB362

June 7, 2016 1:02 AM UTC

Updated data presented at the American Society of Clinical Oncology (ASCO) meeting showed IMAB362 from Ganymed Pharmaceuticals AG (Mainz, Germany) plus chemotherapy led to longer overall survival (OS) and progression-free survival (PFS) than chemotherapy alone in the Phase II FAST study to treat gastric or gastroesophageal junction cancer. The company had already disclosed that the study met all its endpoints.

The IMAB362 combo led to a median PFS of 7.9 months vs. 4.8 months for chemotherapy alone (HR=0.47; p=0.0001), and a median OS of 13.2 months vs. 8.4 months for chemotherapy alone (HR=0.51; p=0.0001). PFS was the study's primary endpoint. The data were from 161 patients in two arms of the study. ...